ReviewFrontiers in pharmacology2025
Harnessing marine algal polysaccharides for combination cancer therapy: pharmacological mechanisms and clinical perspectives.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fucoidan-Based Combination Strategies in Cancer Therapy: Biological Basis, Current Evidence, and Future Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Algal polysaccharides (APs) have attracted increasing interest in recent years as adjunctive agents in cancer therapy due to their abundance, low toxicity, and diverse bioactivity. This review explores the pharmacological effects and mechanisms of APs in combination with chemotherapy, radiotherapy, and immunotherapy, as well as their potential as a nano medicine delivery system. It highlights a wide range of biological activities exhibited by APs in combination therapy, including enhanced tumor cell killing, modulation of the tumor immune microenvironment, and protection of healthy tissues from treatment-related toxicity. Furthermore, the review summarizes the advancements in the pharmacodynamics, pharmacokinetics, and safety profiles of APs, emphasizing the need for standardized raw materials, combined strengths analysis, and clinical validation as key future directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.